Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
PLoS One ; 13(10): e0205526, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30304066

RESUMEN

Staphylococcal extracellular polymeric substances (EPS) such as extracellular DNA (eDNA) and poly-N-acetylglucosamine surface polysaccharide (PNAG) mediate numerous virulence traits including host colonization and antimicrobial resistance. Previous studies showed that EPS-degrading enzymes increase staphylococcal biocide susceptibility in vitro and in vivo, and decrease virulence in animal models. In the present study we tested the effect of EPS-degrading enzymes on staphylococcal skin colonization and povidone iodine susceptibility using a novel in vivo pig model that enabled us to colonize and treat 96 isolated areas of skin on a single animal in vivo. To quantitate skin colonization, punch biopsies of colonized areas were homogenized, diluted, and plated on agar for colony forming unit enumeration. Skin was colonized with either Staphylococcus epidermidis or Staphylococcus aureus. Two EPS-degrading enzymes, DNase I and the PNAG-degrading enzyme dispersin B, were employed. Enzymes were tested for their ability to inhibit skin colonization and detach preattached bacteria. The effect of enzymes on the susceptibility of preattached S. aureus to killing by povidone iodine was also measured. We found that dispersin B significantly inhibited skin colonization by S. epidermidis and detached preattached S. epidermidis cells from skin. A cocktail of dispersin B and DNase I detached preattached S. aureus cells from skin and increased their susceptibility to killing by povidone iodine. These findings suggest that staphylococcal EPS components such as eDNA and PNAG contribute to skin colonization and biocide resistance in vivo. EPS-degrading enzymes may be a useful adjunct to conventional skin antisepsis procedures in order to further reduce skin bioburden.


Asunto(s)
Antibacterianos/farmacología , Matriz Extracelular de Sustancias Poliméricas/efectos de los fármacos , Povidona Yodada/farmacología , Infecciones Cutáneas Estafilocócicas/tratamiento farmacológico , Staphylococcus aureus , Staphylococcus epidermidis , Animales , Adhesión Bacteriana/efectos de los fármacos , Adhesión Bacteriana/fisiología , Desoxirribonucleasa I/farmacología , Modelos Animales de Enfermedad , Farmacorresistencia Bacteriana/efectos de los fármacos , Farmacorresistencia Bacteriana/fisiología , Matriz Extracelular de Sustancias Poliméricas/enzimología , Femenino , Humanos , Proteínas Recombinantes/farmacología , Infecciones Cutáneas Estafilocócicas/enzimología , Infecciones Cutáneas Estafilocócicas/patología , Sus scrofa
2.
Proc Natl Acad Sci U S A ; 114(32): E6652-E6659, 2017 08 08.
Artículo en Inglés | MEDLINE | ID: mdl-28739897

RESUMEN

Gram-positive bacteria cause the majority of skin and soft tissue infections (SSTIs), resulting in the most common reason for clinic visits in the United States. Recently, it was discovered that Gram-positive pathogens use a unique heme biosynthesis pathway, which implicates this pathway as a target for development of antibacterial therapies. We report here the identification of a small-molecule activator of coproporphyrinogen oxidase (CgoX) from Gram-positive bacteria, an enzyme essential for heme biosynthesis. Activation of CgoX induces accumulation of coproporphyrin III and leads to photosensitization of Gram-positive pathogens. In combination with light, CgoX activation reduces bacterial burden in murine models of SSTI. Thus, small-molecule activation of CgoX represents an effective strategy for the development of light-based antimicrobial therapies.


Asunto(s)
Proteínas Bacterianas/metabolismo , Coproporfirinógeno Oxidasa/metabolismo , Coproporfirinas/biosíntesis , Fármacos Fotosensibilizantes/metabolismo , Fototerapia , Infecciones Cutáneas Estafilocócicas/enzimología , Infecciones Cutáneas Estafilocócicas/terapia , Staphylococcus aureus/metabolismo , Animales , Proteínas Bacterianas/genética , Coproporfirinógeno Oxidasa/genética , Coproporfirinas/genética , Modelos Animales de Enfermedad , Ratones , Staphylococcus aureus/genética
3.
Semin Thromb Hemost ; 41(4): 433-44, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-25973589

RESUMEN

Staphylococcus aureus is a leading cause of skin and soft tissue infections, foreign body infections, and infective endocarditis. In case of endovascular infection with S. aureus, higher rates of cardiac valve destruction, embolic complications, severe sepsis, and death occur. The unique capacity of S. aureus to induce clotting has been known for over a century; however, its role in virulence has long been controversial. S. aureus secretes two coagulases, staphylocoagulase and von Willebrand factor binding protein that both activate prothrombin to generate fibrin. A better understanding of the molecular mechanisms as well as the new strategies to target the coagulases have highlighted their importance in S. aureus virulence. Coagulase activity is essential for the formation of S. aureus-fibrin-platelet microaggregates and for the homing of S. aureus to the vascular wall under flow. Absence or inhibition of S. aureus coagulase activity improved outcome in disease models of skin infection, sepsis, catheter infection, and endocarditis. Here, we review how the manipulation of the host's hemostatic system contributes to the disease-causing potential of S. aureus and discuss the S. aureus coagulases as promising targets for novel therapeutic strategies.


Asunto(s)
Coagulación Sanguínea , Coagulasa/metabolismo , Endocarditis Bacteriana/tratamiento farmacológico , Sepsis/tratamiento farmacológico , Infecciones Cutáneas Estafilocócicas/tratamiento farmacológico , Staphylococcus aureus , Animales , Coagulasa/antagonistas & inhibidores , Endocarditis Bacteriana/enzimología , Humanos , Sepsis/enzimología , Infecciones Cutáneas Estafilocócicas/enzimología , Staphylococcus aureus/enzimología , Staphylococcus aureus/patogenicidad
4.
PLoS Pathog ; 10(2): e1003918, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24586149

RESUMEN

Interleukin-33 (IL-33) is associated with multiple diseases, including asthma, rheumatoid arthritis, tissue injuries and infections. Although IL-33 has been indicated to be involved in Staphylococcus aureus (S. aureus) wound infection, little is known about how IL-33 is regulated as a mechanism to increase host defense against skin bacterial infections. To explore the underlying intricate mechanism we first evaluated the expression of IL-33 in skin from S. aureus-infected human patients. Compared to normal controls, IL-33 was abundantly increased in skin of S. aureus-infected patients. We next developed a S. aureus cutaneous infection mouse model and found that IL-33 was significantly increased in dermal macrophages of infected mouse skin. The expression of IL-33 by macrophages was induced by staphylococcal peptidoglycan (PGN) and lipoteichoic acid (LTA) via activation of toll-like receptor 2(TLR2)-mitogen-activated protein kinase (MAPK)-AKT-signal transducer and activator of transcription 3(STAT3) signaling pathway as PGN and LTA failed to induce IL-33 in Tlr2-deficient peritoneal macrophages, and MAPK,AKT, STAT3 inhibitors significantly decreased PGN- or LTA-induced IL-33. IL-33, in turn, acted on macrophages to induce microbicidal nitric oxygen (NO) release. This induction was dependent on inducible nitric oxide synthase (iNOS) activation, as treatment of macrophages with an inhibitor of iNOS, aminoguanidine, significantly decreased IL-33-induced NO release. Moreover, aminoguanidine significantly blocked the capacity of IL-33 to inhibit the growth of S. aureus, and IL-33 silencing in macrophages significantly increased the survival of S. aureus in macrophages. Furthermore, the administration of IL-33-neutralizing antibody into mouse skin decreased iNOS production but increased the survival of S. aureus in skin. These findings reveal that IL-33 can promote antimicrobial capacity of dermal macrophages, thus enhancing antimicrobial defense against skin bacterial infections.


Asunto(s)
Interleucinas/inmunología , Macrófagos/inmunología , Óxido Nítrico Sintasa de Tipo II/inmunología , Piel/enzimología , Infecciones Cutáneas Estafilocócicas/inmunología , Animales , Western Blotting , Modelos Animales de Enfermedad , Activación Enzimática/inmunología , Humanos , Interleucina-33 , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Óxido Nítrico Sintasa de Tipo II/metabolismo , Reacción en Cadena en Tiempo Real de la Polimerasa , Piel/inmunología , Piel/microbiología , Infecciones Cutáneas Estafilocócicas/enzimología , Staphylococcus aureus
5.
J Biol Chem ; 288(9): 6417-26, 2013 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-23322784

RESUMEN

Staphylococcus aureus infections present an enormous global health concern complicated by an alarming increase in antibiotic resistance. S. aureus is among the few bacterial species that express nitric-oxide synthase (bNOS) and thus can catalyze NO production from L-arginine. Here we generate an isogenic bNOS-deficient mutant in the epidemic community-acquired methicillin-resistant S. aureus (MRSA) USA300 clone to study its contribution to virulence and antibiotic susceptibility. Loss of bNOS increased MRSA susceptibility to reactive oxygen species and host cathelicidin antimicrobial peptides, which correlated with increased MRSA killing by human neutrophils and within neutrophil extracellular traps. bNOS also promoted resistance to the pharmaceutical antibiotics that act on the cell envelope such as vancomycin and daptomycin. Surprisingly, bNOS-deficient strains gained resistance to aminoglycosides, suggesting that the role of bNOS in antibiotic susceptibility is more complex than previously observed in Bacillus species. Finally, the MRSA bNOS mutant showed reduced virulence with decreased survival and smaller abscess generation in a mouse subcutaneous infection model. Together, these data indicate that bNOS contributes to MRSA innate immune and antibiotic resistance phenotypes. Future development of specific bNOS inhibitors could be an attractive option to simultaneously reduce MRSA pathology and enhance its susceptibility to commonly used antibiotics.


Asunto(s)
Proteínas Bacterianas/metabolismo , Resistencia a la Meticilina , Staphylococcus aureus Resistente a Meticilina/enzimología , Staphylococcus aureus Resistente a Meticilina/patogenicidad , Óxido Nítrico Sintasa/metabolismo , Infecciones Cutáneas Estafilocócicas/enzimología , Absceso/genética , Absceso/microbiología , Absceso/patología , Animales , Antibacterianos/farmacología , Péptidos Catiónicos Antimicrobianos/farmacología , Proteínas Bacterianas/genética , Daptomicina/farmacología , Humanos , Staphylococcus aureus Resistente a Meticilina/genética , Ratones , Mutación , Óxido Nítrico/metabolismo , Óxido Nítrico Sintasa/genética , Especies Reactivas de Oxígeno/metabolismo , Infecciones Cutáneas Estafilocócicas/genética , Infecciones Cutáneas Estafilocócicas/microbiología , Infecciones Cutáneas Estafilocócicas/patología , Vancomicina/farmacología , Catelicidinas
6.
Am J Pathol ; 150(1): 359-69, 1997 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-9006351

RESUMEN

Urokinase-type plasminogen activator (uPA) is thought to be an important mediator in the proteolytic degradation of extracellular matrix components observed in a wide variety of normal physiological and pathological conditions. However, the phenotype of a recently developed strain of urokinase-deficient (uPA-/-) mice appears to be normal when maintained under ideal nonstressful conditions. We report an outbreak of botryomycosis, an unusual staphylococcal infection, in a colony of uPA-deficient mice. A detailed histological examination of these uPA-deficient animals also revealed a variety of previously unreported phenotypic abnormalities such as pleuritis and the effacement of lymphoid follicles in the regional lymph nodes and spleen. Additional phenotypic abnormalities such as dystrophic calcifications and rectal prolapse were also observed in the uPA-deficient population. These abnormalities were also noted in ostensibly healthy uPA-deficient animals. Botryomycosis did not affect a colony of wild-type (uPA+/+) animals maintained concurrently under identical conditions in the same room. The peculiar predisposition of the uPA-deficient animals to this rare bacterial infection and the development of phenotypic abnormalities associated with the targeted disruption the uPA gene suggests that uPA contributes significantly to the cutaneous microenvironment and is additional evidence of the extensive involvement of the plasminogen activators in mammalian physiology.


Asunto(s)
Tejido Linfoide/patología , Pleuresia/genética , Infecciones Cutáneas Estafilocócicas/genética , Activador de Plasminógeno de Tipo Uroquinasa/deficiencia , Activador de Plasminógeno de Tipo Uroquinasa/genética , Absceso/patología , Animales , Movimiento Celular , Susceptibilidad a Enfermedades , Pulmón/patología , Ganglios Linfáticos/patología , Ratones , Ratones Endogámicos , Ratones Mutantes , Pleuresia/enzimología , Pleuresia/patología , Prolapso Rectal/patología , Bazo/patología , Infecciones Cutáneas Estafilocócicas/enzimología , Infecciones Cutáneas Estafilocócicas/patología , Staphylococcus aureus/aislamiento & purificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA